Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 6Phase 1/2 3Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Sarcoma 4Genitourinary 3Gynecologic 2CNS 2Thoracic 1Other hematologic neoplasm 1NET 1Lymphoid 1Endocrine 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

Cytarabine 166Cyclophosphamide 110Daunorubicin 88Methotrexate 83Etoposide 66Vincristine 63Mercaptopurine 55Rituximab 54Dexamethasone 54venetoclax 50fludarabine 47Doxorubicin 46Azacitidine 46Idarubicin 45Asparaginase 42Imatinib Mesylate 41Prednisone 39pegaspargase 37Thioguanine 36Radiotherapy 35Mitoxantrone 35Busulfan 31Peripheral Blood Stem Cell Transplantation 25Leucovorin 25Bendamustine Hydrochloride 25fludarabine phosphate 24Filgrastim 24obinutuzumab 23nilotinib 23Granulocyte Colony-Stimulating Factor 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × X-Rays × Other hematologic neoplasm × Clear all
NCT02003222 2026-05-01

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡